STOCK TITAN
  1. Home
  2. IMUND

IMUND (IMUND) Stock Price, News & Analysis

IMUND
Published by Stock Titan Data refreshed

What Changed

Company Description

This page collects what Stock Titan holds for IMUND, including price data and latest news.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky

—

Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV

—

Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH

fda approval
—

Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies

—

Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction

—

Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development

—

Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors

management
—

Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes

—

Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer

management
—

Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer

management

IMUND has 10 recent news articles. Key topics include fda approval, management. View all IMUND news →

SEC Filings

View All

No SEC filings available for IMUND.